By Chad Hafer, Director of MSAT at Kindeva
Demand for glucagon-like peptide-1 (GLP-1) agonists and other complex injectable therapies is intensifying pressure across sterile manufacturing networks. The global fill finish market is expected to grow at a compound annual growth rate of 8.9% and to reach $28.14 billion by 2030 [1]. As demand for high-volume products continues to rise, manufacturers must increase output while maintaining the process consistency needed for reliable commercial production. This pressure can expose gaps in process understanding, particularly when scale-up progresses faster than knowledge of how a molecule will behave under real-world manufacturing conditions.
Fill finish performance depends on decisions made upstream and even highly automated aseptic filling operations rely on bulk drug substances with predictable physical and processing characteristics. Batch-to-batch changes in viscosity, concentration, aggregation tendency or filtration behavior can lead to longer processing times, reduced yield and additional interventions at fill finish. Across repeated commercial campaigns, these deviations can also consume valuable line time and complicate production planning. Building upstream processes that can deliver consistent performance as volumes increase and equipment changes gives downstream operations a more stable starting point and supports more dependable use of constrained fill finish capacity.
In this article, Chad Hafer, Director of MSAT at Kindeva, explores how upstream variability translates into downstream manufacturing risk, and why deeper process understanding is essential to improving fill finish performance as more injectable products move toward commercial scale.
When scale-up outpaces process knowledge
A persistent upstream challenge is process scale increasing faster than process knowledge. At a small scale, a formulation may appear stable because equipment is easier to control, volumes are limited and deviations may be less pronounced. Once the same process moves into a larger manufacturing environment, it encounters different conditions that may not have been fully represented during development.
Rapid scale-up can leave gaps in understanding how a molecule behaves under real-world manufacturing conditions, how sensitive it is to mixing, temperature or filtration and how much variability the process can tolerate before critical quality attributes (CQAs) begin to shift. These process gaps are especially relevant for products moving quickly toward commercialization where market demand can create strong pressure to expand output without extending development timelines.
Upstream variables can also interact in ways that make later deviations difficult to trace. Variability can develop gradually as the process moves through preparation and transfer, with small shifts in processing conditions changing how the formulation behaves. These effects may not become apparent until fill finish, where changes in fluid properties can disrupt transfer or filling performance. Connecting those downstream observations with the earlier processing history helps teams identify where variability was introduced and which upstream conditions are most likely to have contributed.
Where upstream variability surfaces downstream
When upstream fill finish with inconsistent properties, the filling operation can become unpredictable and intervention-dependent. These inconsistencies typically appear through several recurring manufacturing challenges:
- Batch-to-batch differences in viscosity or concentration: Changes in fluid properties can directly affect pump performance and dosing accuracy because filling equipment depends on controlled flow behavior. A batch that moves smoothly through the system may behave differently from the next even when both were manufactured to the same nominal process.
- Unexpected yield loss during filtration or transfer: Inconsistent bulk drug substance can behave unpredictably during final filtration or fluid transfer, reducing the amount of usable product available for filling. For high-value biologics manufactured at commercial scale, even modest losses at this stage can have substantial economic consequences.
- Premature filter fouling: Variability in particulate burden, impurities or molecular aggregation can cause filters to reach capacity earlier than expected. This can lead to interruptions or additional operator interventions during a stage where sterility assurance and disciplined execution are critical.
- Reduced throughput and additional interventions: Fluid deviations may require adjustments, slower line speeds or more frequent intervention, increasing operational complexity and potentially elevating contamination risk. In an environment where products may be competing for constrained fill finish capacity, upstream inconsistency can magnify scheduling pressure by turning planned manufacturing time into troubleshooting time.
The most effective response is to detect process drift before bulk product reaches the (GMP) filling line. Stabilizing the formulation upstream protects batch integrity and allows fill finish to operate within a more predictable range. This shifts the focus from correcting downstream symptoms to understanding the variables that created them.
Turning critical process parameters into practical process control
A robust upstream process depends on critical process parameters (CPPs) that reflect actual manufacturing conditions rather than idealized laboratory settings. Some of the parameters most likely to be under-defined during development are also those that appear relatively simple at bench scale but become more consequential when transferred to commercial-scale equipment:
- Mixing speed and duration: At larger volumes, unoptimized mixing can create localized concentration gradients or contribute to product degradation. Conditions that appear relatively forgiving at bench scale may become much more significant once mixing dynamics change in larger vessels.
- Hold times and temperatures: Longer processing periods and inappropriate temperature exposure can increase the risk of molecular instability, aggregation or microbial groerstanding acceptable boundaries increasingly important as batch size and processing duration increase.
- Filtration pressure and flow: Settings that perform adequately during development may influence membrane fouling, shear stress or product yield when transferred to different equipment or larger-scale systems. For complex biologics and other sterile injectables, filtration performance needs to be understood in the context of commercial-scale manufacturing.
- Shear and foaming sensitivity: Excessive mechanical energy can damage sensitive protein products and affect molecular integrity. Establishing how a formulation responds to mechanical stress helps define appropriate processing conditions before scale-up.
The value of monitoring CPPs comes from knowing the proven operating range and understanding what happens as the process approaches its boundaries. Fixed target values alone provide limited protection if teams do not know how much movement the process can tolerate. Establishing realistic ranges early gives manufacturing teams a stronger basis for control during technology transfer and routine production.
Testing process assumptions before GMP production
Pre-GMP production runs provide a controlled way to test whether development assumptions remain valid under manufacturing conditions before they are carried into validated production. Teams can intentionally bracket conditions, challenge operating limits and observe how the product responds to the equipment that will be used at scale. This process helps reveal hidden sensitivities, assess whether proposed CPPs are realistic and identify areas that require tighter control before validation.
Testing process assumptions before GMP production establishes a process that remains reliable across an acceptable operating window. Engineering data can show why a process works, how much variation it can tolerate and where meaningful risks begin to emerge. For sterile injectable products moving toward large-scale supply, this information can be particularly valuable because it reduces the amount of optimization needed during GMP manufacture, when schedule pressure and the cost of disruption are both higher.
In tech transfer, a process transferred as a set of instructions leaves the receiving team with limited context if performance begins to drift. A process transferred with defined CPPs, product sensitivity data, filtration characterization and representative batch history gives the manufacturing team a much clearer basis for predicting behavior and responding consistently.
Building process knowledge into technology transfer
Successful technology transfer depends on understanding how the formulation behaves and how the process responds when parameters move within or beyond defined boundaries. Evidence-based CPP ranges provide a foundation for control, while a clear profile of product sensitivities helps teams understand responses to mechanical and environmental stress. Filtration and mixing characterization can help anticipate interactions with production equipment and representative batch history provides a baseline for distinguishing normal variation from meaningful process drift.
A formulation that is stable in bulk must still move consistently through filtration and filling equipment and into the selected primary container without creating new variability. Where the final product is associated with a delivery device, compatibility between formulation, container, device and high-speed fill finish operations becomes part of manufacturing readiness. For injectable products, which may be produced at significant scale and move through tightly coordinated filling and device-related workflows, considering these interactions early can reduce the risk of late-stage changes.
Developers can strengthen transfer readiness by building robustness during the clinical lifecycle, documenting observed operating ranges rather than relying only on ideal setpoints, and designing processes with commercial-scale equipment in mind. Waiting until late-stage transfer to determine how a formulation behaves on production-scale systems compresses the time available to resolve issues and can push process learning into GMP batches.
Containing process risk before it reaches the filling line
Upstream uncertainty should be addressed before the product reaches the filling suite, as resolving issues once they emerge on the filling line can add greater cost and time to the manufacturing process. A structured risk management approach can help prioritize risks before commercial execution:
- Structured risk assessments: Cross-functional assessments can identify the variables most likely to affect product quality or manufacturing execution and highlight where additional data are needed before the process advances.
- Phased process progression: Moving from engineering runs through validation and into GMP manufacture allows process knowledge to build in a controlled sequence, reducing the need to test major assumptions during commercial production.
- Enhanced early-stage monitoring: Increased monitoring and sampling during early batches can help detect fluid anomalies and distinguish expected variation from early signs of process drift before they create greater downstream impact.
- Predefined contingency planning: Clear response plans give operators a framework for managing performance that moves outside the expected range and reduce the need for improvised decision-making during production.
- Rapid cross-functional communication: Close communication between development, technical and manufacturing teams helps connect downstream observations with upstream processing history, making it easier to interpret deviations identified at fill finish.
Flexible formulation environments can reduce physical constraints around critical operations, such as mixing and filtration, while supporting efficient movement through the manufacturing space. Designing facilities to accommodate different equipment configurations and process requirements can also help teams maintain greater control as products progress from development to larger-scale production.
Creating a more reliable path to commercial supply
As demand for increases, manufacturers face continued pressure to increase output while maintaining reliable GMP performance. The filling line is often the point where variability becomes visible, but differences in viscosity, yield loss, filter fouling and processing time can all originate from incomplete upstream understanding.
Manufacturing strategies are therefore more resilient when process knowledge develops alongside manufacturing scale. This includes establishing realistic CPP ranges and using engineering data to challenge development assumptions and understand how the formulation responds to the manufacturing environment. With this process history in place, teams are better equipped to recognize when normal variation is beginning to develop into a more significant manufacturing risk.
For large-scale complex injectable products, where demand can intensify both capacity pressure and the consequences of delay, upstream robustness becomes a key enabler of reliable commercial supply. When the process is well characterized before it reaches the aseptic filling line, technology transfer becomes more controlled, validation becomes more predictable and fill finish can operate as the final execution step of a manufacturing process that has already been thoroughly understood.
References
